Cargando…

Diabetes does not affect outcome in patients with Enterobacteriaceae bacteremia

BACKGROUND: There is limited information about the effect of diabetes on the prognosis of patients with bacterial infections. We performed a retrospective cohort study to investigate possible correlations between diabetes and prognosis in patients with Enterobacteriaceae bacteremia. METHODS: We revi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peralta, Galo, Sánchez, M Blanca, Roiz, M Pía, Garrido, J Carlos, Teira, Ramón, Mateos, Fátima
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2711956/ https://www.ncbi.nlm.nih.gov/pubmed/19523241 http://dx.doi.org/10.1186/1471-2334-9-94

Ejemplares similares

Altered blood glucose concentration is associated with risk of death among patients with community-acquired Gram-negative rod bacteremia
por: Peralta, Galo, et al.
Publicado: (2010)

Time to positivity in blood cultures of adults with Streptococcus pneumoniae bacteremia
por: Peralta, Galo, et al.
Publicado: (2006)

191. Appropriateness of Empiric Antibiotics for Enterobacteriaceae Bacteremia
por: Smith, Brandon J, et al.
Publicado: (2019)

2416. Risk Factors and Outcomes of Bacteremia Caused by Carbapenem-Resistant Enterobacteriaceae Compared With Carbapenem Susceptible Enterobacteriaceae
por: Mahmood, Syed Faisal
Publicado: (2018)

Pseudomonas aeruginosa bacteremia in patients with liver cirrhosis: a comparison with bacteremia caused by Enterobacteriaceae
por: Bang, Ji Hwan, et al.
Publicado: (2013)

Cefmetazole for bacteremia caused by ESBL-producing enterobacteriaceae comparing with carbapenems
por: Fukuchi, Takahiko, et al.
Publicado: (2016)

959 Epidemiology and Treatment of Enterobacteriaceae Bacteremia: Combination vs Monotherapy
por: Berkowitz, Nina, et al.
Publicado: (2014)

Clinical Impact of Revised Cefepime Breakpoint in Patients With Enterobacteriaceae Bacteremia
por: Foong, Kap Sum, et al.
Publicado: (2019)

ESBL- and Carbapenemase-Producing Enterobacteriaceae in Patients with Bacteremia, Yangon, Myanmar, 2014
por: Myat, Tin O., et al.
Publicado: (2017)

Clinical benefit of ertapenem compared to flomoxef for the treatment of cefotaxime-resistant Enterobacteriaceae bacteremia
por: Lee, Chen-Hsiang, et al.
Publicado: (2018)

Mecillinam for the treatment of acute pyelonephritis and bacteremia caused by Enterobacteriaceae: a literature review
por: Jansåker, Filip, et al.
Publicado: (2018)

Factors Associated with Mortality in Carbapenem-Resistant Enterobacteriaceae Bacteremia: Focus on Antibiotic Therapy
por: Pillinger, Kelly E, et al.
Publicado: (2017)

Treatment of sepsis: What is the antibiotic choice in bacteremia due to carbapenem resistant Enterobacteriaceae?
por: Alhashem, Fatema, et al.
Publicado: (2017)

Population Pharmacokinetics of Piperacillin in Non-Critically Ill Patients with Bacteremia Caused by Enterobacteriaceae
por: Merino-Bohórquez, Vicente, et al.
Publicado: (2021)

Predictors of mortality from extended-spectrum beta-lactamase-producing Enterobacteriaceae bacteremia
por: Namikawa, Hiroki, et al.
Publicado: (2023)

Trends in Fluoroquinolone (Ciprofloxacin) Resistance in Enterobacteriaceae from Bacteremias, England and Wales, 1990–1999
por: Livermore, David M., et al.
Publicado: (2002)

Impact of empirical treatment in extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. bacteremia. A multicentric cohort study
por: Peralta, Galo, et al.
Publicado: (2012)

Comparing the Outcomes of Adults with Enterobacteriaceae Bacteremia Receiving Short-Course vs Prolonged-Course Antibiotic Therapy
por: Chotiprasitsakul, Darunee, et al.
Publicado: (2017)

Relation between flomoxef minimum inhibitory concentrations and clinical outcomes of patients treated with flomoxef for Enterobacteriaceae bacteremia
por: Lee, Chen-Hsiang, et al.
Publicado: (2018)

1072. Streamlining to Oral β-Lactam vs. Fluoroquinolone as Definitive Therapy for Enterobacteriaceae Bacteremia
por: Fong, Karen, et al.
Publicado: (2018)

Cefepime Therapy for Cefepime-Susceptible Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae Bacteremia
por: Wang, Ruibin, et al.
Publicado: (2016)

Endogenous Bacteremia Caused by Intestinal Colonization of Carbapenem-Resistant Enterobacteriaceae (CRE) in Immunocompromised Children
por: Almasian Tehrani, Nasim, et al.
Publicado: (2023)

434 Prevalence, Risk Factors, and Outcomes of Bacteremia Caused by Carbapenem-resistant Enterobacteriaceae in Neutropenic Patients with Hematologic Malignancies
por: Satlin, Michael J., et al.
Publicado: (2014)

1599. Clinical Outcomes for Patients Treated with Fluoroquinolones for Bacteremia Caused by Enterobacteriaceae Reclassified as Not Susceptible by Updated CLSI Breakpoints
por: Fleischner, Zachary, et al.
Publicado: (2020)

Carbapenem-resistant Enterobacteriaceae (CRE) or Delayed Appropriate Therapy (DAT)—Does One Affect Outcomes More Than the Other Among Patients With Serious Infections Due to Enterobacteriaceae?
por: Lodise, Thomas, et al.
Publicado: (2017)

Clinical and microbiologic characteristics of cefotaxime-non-susceptible Enterobacteriaceae bacteremia: a case control study
por: Noguchi, Taro, et al.
Publicado: (2017)

518. Comparing the Mortality of Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae Bacteremia
por: Seo, Hyeonji, et al.
Publicado: (2019)

Epidemiology of Carbapenem-Resistant Enterobacteriaceae Bacteremia in Gyeonggi Province, Republic of Korea, between 2018 and 2021
por: Lee, Seung Hye, et al.
Publicado: (2023)

2246. Improved Outcomes for Cancer Patients Treated With Ceftazidime–Avibactam vs. Polymyxin-Containing Regimens for Carbapenem-Resistant Enterobacteriaceae Bacteremia
por: Borjan, Jovan, et al.
Publicado: (2019)

1179. Incidence of Bacteremia and Bacteriuria With Antibiotic-Resistant Enterobacteriaceae After Transrectal Ultrasound-Guided Biopsy of the Prostate (TRUSBP)
por: Saade, Elie, et al.
Publicado: (2018)

Outcome and Safety of Colistin Usage in Pediatric Cancer Patients with Carbapenem-Resistant Enterobacteriaceae Bacteremia at Children Cancer Hospital Egypt
por: Adel, Nagla, et al.
Publicado: (2023)

1055. Epidemiology and Mechanisms of Carbapenem Resistance in Recurrent Extended-Spectrum β-Lactamase- Producing Enterobacteriaceae Bacteremia
por: Aitken, Samuel L, et al.
Publicado: (2018)

1885. Cost-Effectiveness of Ceftazidime–Avibactam Compared With Colistin for Treatment of Carbapenem-Resistant Enterobacteriaceae Bacteremia and Pneumonia
por: Sfeir, Maroun, et al.
Publicado: (2018)

1826. Impact of Rapid Diagnostics and Ceftazidime–Avibactam on Mortality after Bacteremia Caused by Carbapenem-Resistant Enterobacteriaceae
por: Satlin, Michael J, et al.
Publicado: (2019)

211. Disease burden of bacteremia with extended-spectrum beta-lactamase-producing or carbapenem-resistant Enterobacteriaceae in Korea
por: Mi Lee, Chan, et al.
Publicado: (2023)

Evaluation of the INCREMENT-CPE, Pitt Bacteremia and qPitt Scores in Patients with Carbapenem-Resistant Enterobacteriaceae Infections Treated with Ceftazidime–Avibactam
por: Jorgensen, Sarah C. J., et al.
Publicado: (2020)

Bacteremia due to Carbapenem-Resistant Enterobacteriaceae (CRE) in New York and New Jersey: A Clinical and Molecular Epidemiologic Analysis
por: Satlin, Michael, et al.
Publicado: (2015)

Bacteremia Caused by Extended-Spectrum Beta-Lactamase–Producing Enterobacteriaceae in Vientiane, Lao PDR: A 5-Year Study
por: Chang, Ko, et al.
Publicado: (2020)

1588. Clinical Prediction Tool for Extended-Spectrum Β Lactamase-Producing Enterobacteriaceae as the Etiology of Bacteremia in Solid Organ Transplant Recipients
por: Wang, Rebecca, et al.
Publicado: (2018)

Oral Fluoroquinolone or Trimethoprim-Sulfamethoxazole vs ß-Lactams as Step-Down Therapy for Enterobacteriaceae Bacteremia: Systematic Review and Meta-analysis
por: Punjabi, Chitra, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_rbcemn4bvre5hrvqm7hs4tn0i9